At the Jožef Stefan Institute in Slovenia, researchers are working on a new, targeted nanoparticle delivery to specifically target cancer cells. These magnetized nanoparticles seek out cancer cells to deliver the drugs. Through this method, the magnetized nanoparticles are can control the delivery and use less of the medication in the process. When tested in mice, original delivery methods reduced the side of the tumor by 40% in 10 days, but with the targeted drug delivery, the tumor was reduced to 90% of its original size in 10 days. Watch the full report from Reuters here.
At Drug Delivery Partnerships 2012, a workshop entitled "Nanotechnology and RNAi Use for Drug Formulation and Delivery: How Do We Move Closer to Success?" will have insights on similar technologies from Novo Nordisk, Baxter Healthcare, Emergent Technologies. For more information on this workshop and the rest of the program, visit the webpage to download the brochure. Don't forget, as a reader of this blog, when you register for this event and mention code XP1778Blog, you receive a discount of 25% off the standard rate!
Do you think the success of targeted nanoparticle drug delivery will be a great benefit to the industry? What do you see as the diseases that can best profit from this new drug delivery method?
No comments:
Post a Comment